Abstract: Provided herein are compositions comprising peptide amphiphiles, glycosylated peptide amphiphiles (GPAs), supramolecular nanostructures assembled therefrom, and methods of use thereof. The peptide amphiphiles described herein may extend the half-life of bone morphogenic proteins, promote cell differentiation, suppress proliferation, and increase chemosensitivity of cells. Accordingly, the compositions described herein may be used for cancer treatment methods. In particular, provided herein are bone morphogenic proteins bound to peptide amphiphiles and glycosylated peptide amphiphiles or composites thereof, and methods of use of the same for the treatment of cancer. Also, provided herein are bone morphogenic proteins bound to peptide amphiphiles and glycosylated peptide amphiphiles or composites thereof, and methods of use of the same in a combinatorial approach together with chemotherapeutic medications for the treatment of cancer.

Abstract: The present teachings provide methods for providing populations of single-walled carbon nanotubes that are substantially monodisperse in terms of diameter, electronic type, and/or chirality. Also provided are single-walled carbon nanotube populations provided thereby and articles of manufacture including such populations.

Abstract: Provided herein are peptide amphiphile co-assemblies and uses thereof. In particular, the technology relates to peptides that are intercalated into peptide amphiphile nanofibers, and methods of delivering peptide drugs using the same.

Abstract: The present teachings provide methods for providing populations of single-walled carbon nanotubes that are substantially monodisperse in terms of diameter, electronic type, and/or chirality. Also provided are single-walled carbon nanotube populations provided thereby and articles of manufacture including such populations.

Abstract: Provided herein are compositions comprising a composite of peptide amphiphiles and biocompatible particles and methods of use thereof for treatment of bone and/or tissue defects. In particular, compositions comprise a slurry paste of a peptide amphiphile nanofiber solution mixed with solid biocompatible particles, and find use in tissue/bone regeneration, growth factor delivery, and/or cell delivery.

Abstract: Provided herein are glycosylated peptide amphiphiles (GPAs), supramolecular glyconanostructures assembled therefrom, and methods of use thereof. In particular, provided herein are glycosaminoglycan (GAG) mimetic peptide amphiphiles (PAs) and supramolecular GAG mimetic nanostructures assembled therefrom that mimic the biological activities of GAGs, such as heparin, heparan sulfate, hyaluronic acid etc.

Abstract: Provided herein are sulfonate-based water-soluble photoswitches that, in contrast to existing systems, trigger a volumetric expansion in hydrogels upon exposure to photons; contraction is in turn observed under dark conditions in a highly reversible manner.

Abstract: Provided herein is technology relating to compositions comprising sonic hedgehog protein and therapeutic uses thereof. In particular, the technology relates to compositions comprising a hedgehog protein and one or more peptide amphiphiles for use in methods of treating or preventing stress urinary incontinence and/or erectile dysfunction in a subject.

Abstract: Provided herein are peptide amphiphiles (PAs) comprising a bioactive peptide, nanofibers displaying the bioactive PAs, and methods of use thereof. The disclosed peptide amphiphiles comprise a hydrophobic tail, a structural peptide segment, a charged peptide segment, and a bioactive IKVAV peptide. The disclosed PAs may be used in cell culture methods and in methods of treating central nervous system injury.

Abstract: Provided herein are self-assembling peptide amphiphiles (PAs) comprising a bioactive vascular endothelial growth factor (VEGF) peptide, nanofibers displaying VEGF PAs, and methods of treatment or prevention of the polyglutamine disease Spinocerebellar Ataxia Type 1 (SCA1) and other neurodegenerative diseases therewith. In particular embodiments, a VEGF peptide delivery platform is provided in which the mechanical properties of the nanofiber material are tunable by altering the ratio of bioactive PA to structural PAs (e.g., acidic or basic PAs lacking a bioactive epitope).

Abstract: The disclosure relates to compositions and superstructures comprising peptide amphiphiles. In some aspects, the disclosure relates to compositions and superstructures comprising host and guest peptide amphiphiles, wherein the host and guest moieties of the peptide amphiphiles interact via non-covalent interactions to form a supramolecular assembly, such a superstructure. In some aspects, the superstructure further comprises a bioactive moiety. Suitable bioactive moieties may be selected to promote cell growth, migration, and/or differentiation.

Abstract: Provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are targeting PAs comprising a PA backbone and a targeting moiety. In some embodiments, the peptide amphiphiles are assembled into nanofibers.

Abstract: Provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are PEGylated PAs (e.g. nonionic PAs). In some embodiments, the peptide amphiphiles are assembled into nanofibers. The nanofibers may further comprise a growth factor protein, which may bind to a growth factor binding sequence presented on the nonionic PA. In some embodiments, the nanofibers further comprise a charged peptide amphiphile. The charged peptide amphiphile may be bound to a growth factor protein. Further provided herein are methods of use of the peptide amphiphiles and compositions comprising the same, such as for regenerative therapy.

Abstract: Provided herein are compositions comprising peptide amphiphiles, glycosylated peptide amphiphiles (GPAs), supramolecular nanostructures assembled therefrom, and methods of use thereof. The peptide amphiphiles described herein may extend the half-life of bone morphogenic proteins, promote cell differentiation, suppress proliferation, and increase chemosensitivity of cells. Accordingly, the compositions described herein may be used for cancer treatment methods. In particular, provided herein are bone morphogenic proteins bound to peptide amphiphiles and glycosylated peptide amphiphiles or composites thereof, and methods of use of the same for the treatment of cancer. Also, provided herein are bone morphogenic proteins bound to peptide amphiphiles and glycosylated peptide amphiphiles or composites thereof, and methods of use of the same in a combinatorial approach together with chemotherapeutic medications for the treatment of cancer.

Abstract: Provided herein are peptide amphiphiles with binding affinity for the bone promoting growth factor BMP-2, and methods of use thereof. In particular nanofibers and gel scaffolds of BMP-2-binding peptide amphiphiles are provided.

Abstract: Provided herein are peptide amphiphiles (PAs) and supramolecular PA nanostructures that mimic brain derived neurotrophic factor (BDNF), a growth factor that induces neuronal survival, maturation, and increased electrical activity. In particular, injectable biomaterials comprising BDNF mimetic PAs are provided, as well as methods of using BDNF mimetic PAs for the treatment or prevention of neurological injuries, diseases, and disorders.

Abstract: The present teachings provide methods for providing populations of single-walled carbon nanotubes that are substantially monodisperse in terms of diameter, electronic type, and/or chirality. Also provided are single-walled carbon nanotube populations provided thereby and articles of manufacture including such populations.

Abstract: Provided herein are glycosylated peptide amphiphiles (GPAs), supramolecular glyconanostructures assembled therefrom, and methods of use thereof. In particular, provided herein are glycosaminoglycan (GAG) mimetic peptide amphiphiles (PAs) and supramolecular GAG mimetic nanostructures assembled therefrom that mimic the biological activities of GAGs, such as heparin, heparan sulfate, hyaluronic acid etc.

Abstract: Provided herein are glycosylated peptide amphiphiles (GPAs), supramolecular glyconanostructures assembled therefrom, and methods of use thereof. In particular, provided herein are glycosaminoglycan (GAG) mimetic peptide amphiphiles (PAs) and supramolecular GAG mimetic nanostructures assembled therefrom that mimic the biological activities of GAGs, such as heparin, heparan sulfate, hyaluronic acid etc.

Abstract: Provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are targeting PAs comprising a PA backbone and a targeting moiety. In some embodiments, provided herein are therapeutic PAs comprising a PA backbone and a therapeutic agent. In some embodiments, the peptide amphiphiles are co-assembled into nanofibers. In some embodiments, the nanofibers may be used for the treatment of atherosclerosis or related disease.